Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Szentes – page 18

399 clinical trials in Szentes, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Szentes at a glance
399
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

399 trials in Szentes

Open in trial search

Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Vitiligo

Not recruiting

Study of ritlecitinib (50 mg and 100 mg daily) compared to placebo in adults with nonsegmental vitiligo

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Pfizer Inc.

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.

Dermatitis atopic

Not recruiting

Study of Baricitinib for Children and Adolescents with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Rheumatoid arthritis

Not recruiting

Study on the Effectiveness and Safety of Abatacept Biosimilar (DRL_AB) and Methotrexate for Patients with Moderate to Severe Rheumatoid Arthritis

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept
  • Sponsor:Dr Reddy's Laboratories Limited

Psoriatic arthropathy

Not recruiting

Study on Guselkumab for Treating Psoriatic Arthritis in Patients New to Biologic Therapy

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen - Cilag International

Dermatitis atopic

Not recruiting

Study on Long-Term Safety and Effectiveness of Abrocitinib for Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis

Registered drug
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abrocitinib
  • Sponsor:Pfizer Inc.

Colitis ulcerative

Not recruiting

Study on the Effects of Guselkumab and Golimumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years
  • Substances:Golimumab
  • Sponsor:Janssen - Cilag International

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Astrazeneca AB

Arteriosclerosis

Not recruiting

Study of inclisiran to prevent heart attacks and strokes in people with atherosclerotic cardiovascular disease

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma AG

Systemic scleroderma

Not recruiting

Study of anifrolumab effectiveness compared to placebo in adults aged 18-70 with systemic sclerosis

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:Astrazeneca AB

Ischaemic stroke+2

Not recruiting

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Asundexian
  • Sponsor:Bayer AG

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Szentes

What the registry says about research in the country

01 Rheumatology Research

Ongoing clinical trials focusing on Psoriatic Arthritis (PsA) treatments, evaluating novel therapeutic approaches for patients with active disease conditions.

  • Novel Treatment Evaluation
  • Long-term Safety Studies
  • Biologic Therapy Research

Research includes assessment of innovative medications like deucravacitinib and bimekizumab, specifically designed for patients with varying treatment histories.

02 Immunology Studies

Investigation of targeted therapies for autoimmune conditions, with particular emphasis on comparing treatment efficacy against placebo in controlled clinical settings.

  • Treatment Response Analysis
  • Safety Monitoring
  • Patient Tolerance Assessment

Studies focus on both treatment-naïve patients and those with previous exposure to TNFα inhibitors.

03 Therapeutic Development

Comprehensive research into subcutaneous administration of new therapeutic agents for chronic inflammatory conditions.

  • Extended Duration Studies
  • Treatment Efficacy Evaluation
  • Patient Response Monitoring

Trials aim to establish both immediate and long-term benefits of innovative treatment approaches in inflammatory arthritis.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.